SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

Also called NCT05782192

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 458 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05782192
Other papers using this trial's data
  • Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial BMC medicine, 2023-10-09 DOI, PubMed 37814306, PMC10563289 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05782192. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-13 (actual); primary completion 2022-03-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
SAL067
Intervention (Drug)
Alogliptin
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05782192
Content hash
f18e64416c9341e06e2eb04df38bd91458f95b7ebdd3f6d95240270979bff47a